mutation class

Small Mutation

Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma

2 sites for NCT02645149

ALK Fusion, +19 more biomarkers

Melanoma, +1 more condition

ceritinib, +4 more drugs

targeted therapy

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

131 sites for NCT04284774

HRAS Mutation

Histiocytosis, +2 more conditions

tipifarnib

targeted therapy

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol)

1 site for NCT05104567

HRAS Mutation, +2 more biomarkers

Adenocarcinoma of the Gastroesophageal Junction, +3 more conditions

cetuximab, +2 more drugs

immunotherapy, +1 more type

Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer

1 site for NCT04853043

APC Mutation, +4 more biomarkers

Colorectal Adenocarcinoma

cetuximab

targeted therapy

Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome

1 site for NCT04708054

ARAF Mutation, +47 more biomarkers

Acute Myeloid Leukemia, +2 more conditions

busulfan, +5 more drugs

cellular therapy, +1 more type

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

51 sites for NCT03190915

CBL Loss, +8 more biomarkers

Juvenile Myelomonocytic Leukemia, +1 more condition

trametinib

targeted therapy

tipifarnib

HRAS Mutation

Head and Neck Squamous Cell Carcinoma

Metastatic, +1 more state

Subsequent line

tipifarnib

targeted therapy